References
1. Hama, N., et al.,Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. J Allergy Clin Immunol Pract, 2022. 10 (5): p. 1155-1167.e5.
2. Duong, T.A., et al., Severe cutaneous adverse reactions to drugs. Lancet, 2017.390 (10106): p. 1996-2011.
3. Shiohara, T., et al., The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol, 2007. 156 (5): p. 1083-4.
4. Kardaun, S.H., et al.,Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol, 2007. 156 (3): p. 609-11.
5. Brockow, K., et al., EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy, 2019. 74 (1): p. 14-27.
6. Cabañas, R., et al., Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol, 2020. 30 (4): p. 229-253.
7. Brin, C., et al., Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases. Ann Dermatol Venereol, 2021. 148 (3): p. 168-171.
8. Funck-Brentano, E., et al.,Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol, 2015. 72 (2): p. 246-52.
9. Maverakis, E., A. Ji-Xu, and M.C. Brüggen, Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms (DRESS). Allergy, 2022.
10. Jörg, L., et al., The role of drug, dose, and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome. Allergy, 2020. 75 (5): p. 1178-1187.